Reuters logo
BRIEF-GSK gets Canadian approval for bronchodilator treatment Incruse
April 17, 2014 / 3:35 PM / 4 years ago

BRIEF-GSK gets Canadian approval for bronchodilator treatment Incruse

April 17 (Reuters) - Glaxosmithkline Plc :

* Glaxosmithkline plc gsk receives approval in Canada for incruse

* Announces approval in canada for Incruse Ellipta (Umeclidinium) as a treatment for COPD

* Has received market authorisation in Canada for long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema

* Clinical programme for Umeclidinium included seven phase iii clinical trials which involved over 2,500 copd patients treated with umeclidinium or placebo Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below